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and post hoc Tukey test. Statistical analysis of survival time
was carried out with Kaplan-Meier (Log-Rank) test.
Results: The immunized mice with this DNA vaccine pre-
sented an important reduction in diameter of lesion and
increasing of weight compared to the control mice and was
indicated a signiﬁcant difference between the immunized
group and the control groups (p < 0.05). The survival time of
the immunized mice was signiﬁcantly higher than the con-
trol groups (p < 0.05) after challenge with Leishmania major.
The immunized mice had signiﬁcantly lower parasite load
compared to the control mice (p < 0.05).
Conclusion: The ﬁndings of this study, indicated that
the TSA - encoded DNA vaccine induced protection against
infection with Leishmania major in mice. In this study, we
demonstrated that, the TSA -encoded DNA vaccine may be
an excellent candidate for futher vaccine development.
doi:10.1016/j.ijid.2008.05.991
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Background: In endemic countries, Kala-Azar (K) acts
as an opportunistic infection, when a deep HIV-related
immunodeﬁciency is present; infrequently, a cutaneous
spread was described. Case report. An atypical episode
of HIV-associated K complicated by a diffuse, aspeciﬁc
macular-papular cutaneous involvement was characterized
by absent epidemiological clues, a prolonged course, and
no response to repeated cycles of liposomal amphotericin
B (lAB), despite a CD4+ lymphocyte count >500 cells/L,
maintained thanks to a concurrent antiretroviral treat-
ment. Despite a negligible immunodeﬁciency, K serology
proved negative.Only a prolonged administration of the
second-line i.v. pentamidine (12 weeks), together with
oral paromomycin (7 weeks), led to a cure of K and its
related skin dissemination, in absence of toxicity and dis-
ease relapses.
Discussion: The differential diagnosis of skin dissem-
ination of K (which may appear as single, multiple, or
disseminated macules, papules, plaques, nodules, ulcers),
enters in a broad spectrum of possible HIV-associated com-
plications, and may be the clue of a missed K, so that
a biopsy with histopathology-culture becomes mandatory,
since serology is not reliable also when immunodeﬁciency
is limited. The ﬁrst-line treatment of HIV-associated K
is debated. Pentavalent antimony compounds were the
mainstay in the past 70 years, but lAB seems effective
and safe, especially when administered in short courses.
Like in our case, failure of AB in treating K was anecdo-
tally documented. In our particular episode, a prolonged
pentamidine-paromomycin treatment became necessary,
after multiple failures of lAB. An effective antiretroviral
therapy may restore the immune function and signiﬁcantly
help anti-protozoal treatment, but it was not the case of
our patient, who was virologically suppressed and reached a
CD4+ count of >500 cells/L before of the cutaneous spread.
Also in the HAART era, clinicians facing patients with a
well controlled HIV disease, should carefully assess a non-
speciﬁc rash, which may enter in differential diagnosis with
an elevated number of infectious, allergo-toxic, and dysre-
active disorders. Randomized clinical trials are needed to
aid selection of therapeutic regimens of K with/without a
concurrent immunodeﬁciency, and with/without cutaneous-
other complications, due to the increased frequency
of both K and HIV disease, especially in developing
countries.
doi:10.1016/j.ijid.2008.05.992
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Background: Fetal infection by Toxoplasma gondii devel-
ops when non-immune mother becomes infected during
pregnancy. Accurate dating of infection is mandatory to
prevent complications. T.gondii IgM persists in serum for
months after infection, hence, not suitable as an evidence
of recent infection, beside its lack of speciﬁcity. T.gondii
IgG avidity assay is expected to distinguish recent and past
infection. High avidity excludes recent infection in the pre-
ceding 16—20 weeks, while low avidity doesn’t differentiate
recent from old infection. This study evaluated the use of
IgG-avidity assay and IgG and IgM to detect recent toxoplas-
mosis in early pregnancy.
Methods: Sera from 2070 asymptomatic Saudi Arabian
pregnant women at different gestational stages were ﬁrst
screened for T.gondii IgG by indirect hemagglutination test
(Toxocell IHA, biokit, Spain). Enzyme linked ﬂuorescent
assay (ELFA, VIDAS, BioMerieux, France) was used to detect
T.gondii IgM and to measure total IgG and IgG-avidity index
(AI).
Results: Out of 401 IHA-positive sera, 151 (37.7%) sam-
ples were positive for T.gondii IgM, among which AI was
low in 17 samples (11.3%), intermediate in 1 (0.6%), and
high in 133 samples (88.1%). The possibility of recent infec-
tion in IgM-positive sera was excluded with a high IgG AI
(95% CI, 83—93%). High AI was shown in 97.8% of IgM-
negative sera. These ﬁnding minimized the value of a
positive IgM ﬁnding as single indicator for acute recent infec-
tion. Actually, it highlighted the value of IgG avidity assay to
exclude recent infection. No signiﬁcant correlation between
level of IgG, and presence of either low or high AI; or
between IgG level and presence of IgM in serum (r≈ 0.092)
(p < 0.05.).
Conclusion: For early diagnosis of T. gondii infection,
pregnant women should be initially screened for IgG, to
determine the patient’s immune status; followed by IgM
assay of IgG-positive sera. Absence of serum IgM excludes
